Meeting
2020 Gastrointestinal Cancers Symposium
Baseline liver function and outcomes in the phase III REFLECT study in patients with unresectable hepatocellular carcinoma (uHCC).
Authors
Arndt Vogel
Hannover Medical School, Hannover, Germany
Arndt Vogel , Catherine Frenette , Max W. Sung , Bruno Daniele , Ari David Baron , Stephen Lam Chan , Jean-Frédéric Blanc , Toshiyuki Tamai , Min Ren , Howard John Lim , Daniel H. Palmer , Yuko Takami , Masatoshi Kudo
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B: Hepatobiliary Cancer, Neuroendocrine/Carcinoid, Pancreatic Cancer, and Small Bowel Cancer
Track
Hepatobiliary Cancer,Neuroendocrine/Carcinoid,Pancreatic Cancer,Small Bowel Cancer,Other GI Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT01761266
Citation
J Clin Oncol 38, 2020 (suppl 4; abstr 524)
Abstract #
524
Poster Bd #
C5
Abstract Disclosures
Similar Posters
Poster
2021 Gastrointestinal Cancers Symposium
Post hoc analysis in patients (pts) with unresectable hepatocellular carcinoma (uHCC) who progressed to Child-Pugh B (CPB) liver function in the phase III REFLECT study of lenvatinib (LEN).
First Author: Jasmine Huynh
Poster
2020 Gastrointestinal Cancers Symposium
Subsequent anticancer procedures following first-line lenvatinib (LEN): A post hoc analysis from the phase III REFLECT study in unresectable hepatocellular carcinoma (uHCC).
First Author: Angel Alsina
Poster
2023 ASCO Annual Meeting
Efficacy of lenvatinib (LEN) vs sorafenib (SOR) in the first-line (1L) treatment of patients (pts) with unresectable hepatocellular carcinoma (uHCC): A post hoc analysis of patients with nonviral etiology from REFLECT.
First Author: Ari David Baron
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A multicenter, observational, phase 4 study (STELLAR) to evaluate the safety and tolerability of lenvatinib (LEN) in patients with advanced or unresectable hepatocellular carcinoma (uHCC).
First Author: Markus Peck-Radosavljevic